Sichenzia Ross Friedman Ference LLP Represents Aridis Pharmaceuticals in $15 Million Private Placement
PRESS RELEASE – New York, NY – August 25, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, in a private placement of preferred stock and warrants resulting in total gross proceeds of $15,216,241.
Maxim Merchant Capital, a division of Maxim Group LLC, acted as the exclusive placement agent for the offering. The Sichenzia Ross Friedman Ference LLP team was led by Partner Jeff Fessler, Avital Even-Shoshan, Evan Berger and Nazia Khan.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Document Security Systems, Inc. in $5.6 Million Underwritten Public Offering of Common Stock - June 11, 2019
- New Jersey Bureau of Securities Proposes New Rule to Create State-Level Fiduciary Duties For Broker-Dealers, Associated Persons, Investment Advisers and Investment Adviser Representatives - June 11, 2019
- Sichenzia Ross Ference LLP Represents Medicine Man Technologies, Inc. in Private Placement Offering of up to $14 Million - June 11, 2019